Discussing Post-Hoc Data On Ruxolitinib For Nonsegmental Vitiligo, With David Rosmarin, Md

Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD

Expert Insights on Vitiligo: How Do Emerging Treatment Options Have the Potential to Transform Pa...

Practice Point Communications

Expert Insights on Vitiligo: How Do Emerging Treatment Options Have the Potential to Transform Pa...

Practice Point Communications

Advantages and limitations of ruxolitinib for cGvHD

VJHemOnc – Video Journal of Hematology & HemOnc

The ongoing use of ruxolitinib in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

RESPONSE-2 Trial: Ruxolitinib for PV

A Phase I study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

MCP 60 Seconds With Dr Linda Russell on Rheumatologic & HIV Medications

Mayo Proceedings

Discussion Regarding Approval of Ruxolitinib as a New Therapy for Patients w/ Polycythemia Vera

Ace Your Med School Interview: NHS Hot Topics - Antibiotic Resistance | PostGradMedic

Dr Ollie Burton

Post Hoc Analysis of the ORAL Surveillance Study

Dr John D Pauling explains Anti Topoisomerase 1

Discussing Treatment Options with Patients

Phase II study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Vitiligo treatment1: intro, immunomodulating agents: corticosteroids, calcineurin and JAK inhibitors

Stream of consciousness

Stereology in Pathology Image Analysis - When to use it and when not?

Aleksandra Zuraw Digital Pathology Place

Interview 14 – Standardized measures for lupus treatment and care

Arthritis Broadcast Network

2024 Program Description

uOttawa Dept. Radiology, Rad Onc & Medical Physics